MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that the first patient has been treated with the newly launched QUELIMMUNE™ therapy in a commercial setting at Cincinnati Children’s. QUELIMMUNE, manufactured for SeaStar Medical (Nasdaq: ICU) and exclusively licensed and distributed in U.S. pediatric hospitals by Nuwellis,... Read more
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced an analysis published by the Innovation Value Institute (IVI) titled “Introduction of AI assisted Digital Health Technology to Improve... Read more
Second Quarter Revenue Increased 23% Year-Over-Year
Raising Full Year 2024 Total Omnipod Revenue Outlook ACTON, Mass. / Jul 26, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced certain preliminary revenue results for the three months ended June 30, 2024. The Company plans to report full second quarter 2024 financial results on... Read more
Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo., July 25, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2024.
Key Second Quarter Highlights and Business Update Q2 2024 orders... Read more
SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues.
Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands,... Read more
BELGRADE, MT / ACCESSWIRE / July 25, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will attend the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase being held August 13-15, 2024 at the InterContinental Boston, an... Read more
Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the MyoVista® wavECGTM has been selected by the Innovation Value Institute as a technology which can drive the radical transformation... Read more
Definitive agreement sells out the 10mL SoloGard production capacity at Sharps’ manufacturing site in the EU and drives expansion to support the project’s growth in the future
Sharps’ portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes
Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June... Read more
MARLBOROUGH, Mass. / Jul 25, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Endomagnetics Ltd (Endomag), a privately held UK-based developer of breast cancer surgery technologies, for approximately $310 million.
“We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies,... Read more
In a study conducted by Brigham & Women’s Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards’ Winner
In a study conducted by Jefferson Einstein Hospital, Nanox.AI Cardiac Solution Flags CAD High-Risk Patients, Drives Significant Revenue
Additional data presented by Corewell Health, Massachusetts General Hospital and Rabin Medical... Read more
Continued strong performance with 2Q24 financial results
Raising full year 2024 profit outlook PLANO, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended June 28, 2024.
Second Quarter 2024 Highlights (compared to Second Quarter 2023, except as noted) Sales increased 9% to $436 million, with organic growth of 5%.
GAAP net income increased $7 million to $31 million, an... Read more
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024
Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 ROOT, Switzerland / Jul 25, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive... Read more
Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology
Biomarker discovery market estimated by third party research to be $51.5 billion in 2024 PITTSBURGH, July 25, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it is expanding its AI/ML driven drug discovery platform to pursue discovery of... Read more
Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J., July 25, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics... Read more
Conference Call Scheduled for 9 a.m. EDT Today EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance.
Second-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%.
Reported-diluted EPS of $1.51, compared to $2.06 in the same period last... Read more
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that Intuitive President David J. Rosa has been appointed to the Company’s Board of Directors, effective July 24, 2024.
Rosa joins Intuitive CEO Gary S. Guthart, PhD, as one of two Intuitive executives on the Company’s Board. As president, Rosa manages Intuitive’s core business... Read more
IRVINE, Calif. / Jul 24, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.
Edwards has entered into an agreement to acquire JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant... Read more
IRVINE, Calif. / Jul 24, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2024.
Highlights and Outlook Q2 sales grew 7%; constant currency1 sales grew 8%
Q2 TAVR sales grew 5%; constant currency1 sales grew 6%
Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth
Q2 EPS of $0.61; adjusted1 EPS of $0.70
Significant TAVR and TMTT clinical evidence to be presented at TCT in October 20... Read more
Completion of first EOS Insight-informed surgery kickstarts trajectory towards revolutionized spine care CARLSBAD, Calif. / Jul 24, 2024 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the commercial launch of EOS Insight, a groundbreaking, end-to-end spine surgery platform powered by standardized EOSedge™ scans and AI. With the first customer i... Read more
DALLAS, July 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a 30% increase in its patent portfolio that strengthens and protects its proprietary, AI-driven DeepView System wound assessment platform.
Total patents granted to the Company increased to 26 through July... Read more
RESEARCH TRIANGLE PARK, N.C., July 24, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced that The Rocky Mountain Hospital for Children in Denver, Colorado, part of HCA Healthcare’s HealthONE network, has entered into an agreement to utilize a Senhance® Surgical System.
“We are thrilled to announce the first dedicated pediatric hospital placement of a Senhance® System... Read more
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million... Read more
WAYNE, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit led by Chuck Gartner, Director of Marketing - Strategic Initiatives.
The Teleflex Center for Antimicrobial Protection, located in Research Triangle, North Carolina, is dedicated to reducing... Read more
Three New Patents Granted in the US and Europe SAN FRANCISCO / Jul 23, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has received patent grants from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO): US Patent 12,011,592 and European Patent EP3615133, both titled “Adaptive Trigger... Read more
ROSELAND, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Novitas Solutions, Inc. (Novitas), a Jurisdictional Medicare Administrative Contractor (JMAC), has granted a Medicare Part B Physician payment rate for the Company’s CompuFlo® Epidural System under the American Medical Association’s (AMA) technology-specific... Read more
MASON, Ohio / Jul 23, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products Administration (NMPA) of China to market and sell several models of its AtriClip® Left Atrial Appendage (LAA) Exclusion System.
The AtriClip... Read more
Quarterly EsoGuard® test volume increased 31 percent sequentially NEW YORK, July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it performed a record number of commercial EsoGuard® Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent... Read more
PALM BEACH GARDENS, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio. The launch expands ZimVie’s portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market... Read more
MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced today the publication of the reimbursement of Inspire therapy in France.
“We are thrilled to offer our clinically proven treatment option for moderate to severe OSA to patients and physicians... Read more
DALLAS, July 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added three new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: University Medical Center (UMC) Burn Center at Texas Tech University Health Sciences Center led by principal investigator... Read more
RESEARCH TRIANGLE PARK, N.C., July 23, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for an expanded indication to treat adult and pediatric Urology patients with the Senhance® Surgical System.
“This FDA clearance marks another milestone for Asensus Surgical and represents... Read more
HORSHAM, Pa., July 23, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the issuance and sale of 665,136 shares of its common stock at an average purchase... Read more
Azenta will provide proteomics technology profiling on up to 20,000 individuals. BURLINGTON, Mass., July 22, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced its participation in the FinnGen project, a large-scale research initiative at the forefront of personalized medicine in Finland. The FinnGen project is a pioneering endeavor that has collected and is currently analyzing genomic and health data from a cohort of 500,000 Finnish biobank participants.
In... Read more
Calgary, Alberta – TheNewswire - July 22, 2024 - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in vision enhancement technology, is pleased to announce that its intraocular lenses are now being manufactured for the upcoming first-in-human study in the Dominican Republic.
“We are thrilled to collaborate with Bioana, leveraging their medical device expertise and cutting-edge manufacturing facilities... Read more
Demand for minimally invasive breast cancer treatment was overarching theme of the conference
In one independent study led by Professor Fukuma, 389 patients treated for up to 10 years had 99.74% recurrence free rate
Another independent study led by Professor Kawamoto found 0% breast cancer local recurrence in five-year follow up
ProSense® expected to gain further traction in Japan, as distribution partner Terumo Corporation plans to submit application to the Phar... Read more
Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process
Marks MIMEDX’s first publication in the 5th most-cited journal in the world MARIETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of a peer reviewed study characterizing a potential mechanism by... Read more
HORSHAM, Penn., July 22, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the approval of its XTRAC Momentum™ 1.0 device by the Ministry of Health, Labor and Welfare of Japan. The Company initially launched the XTRAC Momentum™ in the U.S. in early 2022.... Read more
Purchase price of CAD$2.25 per Hamilton Thorne share represents enterprise value of approximately CAD$388 million (US$282 million).
Represents a premium of approximately 54% to the closing price on the Toronto Stock Exchange (“TSX”) of Hamilton Thorne shares on July 19, 2024, the last trading day prior to the announcement of the transaction, and approximately 62% to the 90-day VWAP as of the same date1.
The Board of Directors of Hamilton Thorne (with interested... Read more
REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company's proprietary AI Cloud platform.
The latest version of Biotricity's AI Cloud has improved the company's tech stack efficiency by 20%,... Read more
Robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and 2 studies in patients with deep infiltrating endometriosis
At three months post procedure, the study’s primary endpoint of reduced acute pelvic pain in the HIFU treatment arm compared to the Sham treatment arm was not met
Significant improvements were observed across primary and secondary outcome measures (endometriosis and digestive symptoms)... Read more
MINNEAPOLIS, July 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that the European Union Medical Device Regulation (EU MDR) has approved additional magnetic resonance imaging (MRI) scan conditions for use with Inspire therapy. This full-body MRI approval... Read more
MINNEAPOLIS, July 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced CE mark certification under the European Union’s Medical Device Regulation (EU MDR 2017/745) for Inspire therapy.
“Inspire has a long history of compliance to the European Union’s... Read more
SUNNYVALE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2024.
Q2 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2023.
The Company placed 341 da Vinci surgical systems, compared with 331 in the second quarter... Read more
The 30-patient study is designed to measure the efficacy of applying NEXGEL’s hydrogel during laser hair removal in eliminating harmful particles or plume during treatments
Several states have already either instituted or are considering surgical plume protection mandates as a requirement to contain the toxic byproduct of laser procedures LANGHORNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading... Read more
Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri® in Addition to Currently Recommended Cancer Screenings
Study Enrollment Includes Focus on Diverse and Underrepresented Populations
Costs of Galleri and Related Items and Services for Study Participants Will be Covered by Medicare MENLO PARK, Calif., July 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare... Read more
NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of biocompatibility testing of its Intelligent Fingerprinting Drug Screening System, a pivotal phase in the clinical study plan required for FDA 510(k) regulatory clearance.
The biocompatibility study, conducted in accordance... Read more
BRAINTREE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces it has received Institutional Review Board (IRB) approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Center, located in New York City, New York. Memorial Sloan Kettering Cancer Center will conduct the clinical trial as part of the Investigational Device Exemption... Read more
Sales of $10.4 billion driven by strong underlying base business performance
Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical Devices
Continues to strengthen portfolio with new product approvals ABBOTT PARK, Ill., July 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024. Second-quarter GAAP diluted... Read more
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close.
Investors and analysts are invited to listen to the live broadcast review of the Company’s 2024 second quarter on... Read more
The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list. GUILFORD, Conn. / Jul 17, 2024 / Business Wire / Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced the clearance of the ninth generation of AI-powered Swoop®... Read more
